Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
429 active trials16 approved drugs20 evidence items
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,176 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03734653 | Testosterone Therapy in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03987217 | Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients | completed | Early Phase 1 | 73 | University of UtahOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03661437 |
| Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy |
| completed |
| Early Phase 1 |
| 33 |
| City of Hope Medical CenterOTHER |
| 1 |
| Apr 11, 2025 |
| clinicaltrials |
| NCT05725070 | Phase 0/1 Study of 212Pb-NG001 in mCRPC | completed | Early Phase 1 | 3 | ARTBIO Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04976257 | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | completed | Early Phase 1 | 5 | Ryan Kohlbrenner, MDOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04282824 | Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer(MSG PSMA PET) | completed | Early Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02646319 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | completed | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01050842 | Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Mar 23, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Nov 6, 2025source: clinicaltrials